Novo Nordisk's Nanexa Licensing Deal Lands as CFRA Turns Bearish on the GLP-1 Giant

Novo Nordisk signs a licensing deal with Nanexa worth up to EUR 1.165 billion, as CagriSema data and 2035 revenue targets draw investor focus.

Novo Nordisk capped a turbulent week with a fresh pipeline-building move, signing a worldwide licensing and collaboration agreement with Swedish drug delivery specialist Nanexa on Friday. The deal, centred on Nanexa's proprietary PharmaShell technology, could be worth as much as EUR 1.165 billion to the Swedish partner — a figure that includes EUR 615 million in upfront, development and regulatory milestone payments.

Under the arrangement, the Danish pharmaceutical group secures exclusive rights to deploy PharmaShell across as many as five development programmes, with a focus on long-acting injectables targeting obesity, type 2 diabetes and other cardiometabolic conditions. Novo Nordisk will shoulder worldwide development and commercialisation of the resulting product candidates.

The tie-up fits a broader push by the company to widen its technological footprint in metabolic medicine. Extended-release formulations are seen as a key lever in treating chronic metabolic disease, since longer dosing intervals tend to improve patient adherence. Novo Nordisk is simultaneously pursuing oral therapies: CEO Mike Doustdar told Reuters on Tuesday that oral weight-loss drugs could account for as much as half of the global obesity medicine market by 2030, underscoring a twin-track strategy spanning injectables and pills.

The company is also modernising how it documents its science. In research and development, Novo Nordisk has partnered with Anthropic to harness Claude AI models, compressing the production of study reports from months to mere minutes.

CagriSema Data Draws Both Praise and Scrutiny

Investor attention, however, remains fixed on CagriSema, the company's most closely watched pipeline asset. Phase 3 results released on 21 September showed adults with type 2 diabetes achieving an estimated average weight loss of 12.4% after roughly 60 weeks of treatment, against 9.1% for Eli Lilly's tirzepatide. In a separate late-stage obesity trial, CagriSema at a 1.0 milligram dose delivered a 21% reduction in weight versus placebo. The 1 milligram dose also proved superior to 5 milligrams of tirzepatide in the diabetes study.

Novo Nordisk has said it will now align the regulatory pathway for the type 2 diabetes indication with health authorities. That step carries growing urgency, as the market — after a stretch of muted responses to strategic announcements — is demanding hard evidence of future market leadership rather than promises.

The central question for investors is whether the company can defend its therapeutic edge in the lucrative metabolic disease arena. A roughly three-percentage-point efficacy advantage over tirzepatide gives the Danes a visible lead, though that edge must still hold up in regulatory practice. If Novo Nordisk can demonstrate the clinical benefit comes without a tolerability penalty, it would cement the foundation for the post-semaglutide era. Should the therapeutic gap be judged marginal by regulators and physicians, future premium pricing comes under pressure.

A Bull Case Built on 2035 Targets

In the optimistic scenario, Novo Nordisk steers CagriSema swiftly through approval and establishes it as a superior next-generation therapy. That would underpin the company's long-range ambitions: risk-adjusted pipeline revenue exceeding DKK 150 billion by 2035, alongside a goal of launching more than five products with multi-blockbuster potential by 2030.

Set against that stands a thicket of near-term risks weighing on the valuation. Reuters reported that market participants have found the group's longer-term growth ambitions sobering of late. Evan Seigerman of BMO noted that annual revenue growth of 3.6% is already priced into the stock. On Tuesday, CFRA downgraded Novo Nordisk's US depositary receipts from Hold to Sell, attaching a USD 38 price target.

Beyond intensifying price competition and looming patent expirations, management itself has conceded that its 2030 targets carry uncertainties and do not constitute a binding financial forecast. Should market growth flatten sooner than expected, the operating margin faces a stern test.

Friday's Close and the Road to Milan

The stock's reaction to the Nanexa agreement was restrained. Shares finished Friday at EUR 34.05, up a modest 0.2%. Year to date, the equity has shed 23%, and it now sits 38% below its 52-week high — a reflection of the fierce competitive intensity in obesity therapies.

For investors, the picture narrows to one question: confirmation of clinical superiority. So long as regulatory progress on CagriSema stays on track and the efficacy data hold up in head-to-head comparison, Novo Nordisk retains a potent counterweight to competitive pressure. If confidence in pricing power erodes, or if regulatory steps toward approval slip, the stock's downtrend is likely to persist.

The next concrete milestone is imminent. From 28 September to 2 October, the company will present 44 pieces of research on semaglutide, CagriSema and zenagamtid at the annual meeting of the European Association for the Study of Diabetes in Milan. Those presentations will provide the next test of the pipeline's durability.